Last Update 07 Apr 26

CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential

Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations.

Analyst Commentary

Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event. The focus is on how these updated inputs affect the valuation framework and the margin of safety around Cellebrite DI's equity story.

Bullish Takeaways

Bullish analysts still see support for the current valuation based on their revenue and margin assumptions, even after recalibrating discount rates and long term growth inputs.
The revised P/E expectations are being treated as a fine tuning exercise rather than a reset, which suggests ongoing conviction in the business model if execution stays on track.
The relatively modest $2 price target move signals that, in their view, the core investment case remains intact under updated rate and growth scenarios.
Some bullish analysts appear comfortable that current profit margin assumptions leave room for upside if management delivers on operational efficiency and disciplined cost control.

Bearish Takeaways

Bearish analysts view higher or more conservative discount rate assumptions as a headwind for Cellebrite DI's valuation, especially for investors focused on longer dated cash flows.
More cautious long term revenue growth inputs indicate concern that the previous targets may have been optimistic relative to the company’s execution and market conditions.
Lower profit margin assumptions highlight risk around cost inflation, investment needs, or pricing, which could limit earnings power versus earlier expectations.
More restrained future P/E expectations point to a risk that the market may not be willing to pay as high a multiple as before, particularly if growth or execution comes in at the lower end of prior assumptions.

What's in the News

Cellebrite announced its Spring 2026 Release, expanding device access to a wide range of iOS and Android devices, including support for iPhone 17 and iOS 26. The release also introduces Corellium availability on Google Cloud infrastructure in public preview (Key Developments).
The Spring 2026 Release adds Safeguard Mode to streamline data capture in time-sensitive situations and introduces drone forensics intended to extract and analyze data such as flight logs, video and geolocation artifacts from many unmanned aerial systems (Key Developments).
Corellium by Cellebrite is described as addressing use cases for automotive and industrial systems manufacturers by virtualizing Arm-based systems in the cloud so teams can test different vehicle environments without physical infrastructure (Key Developments).
Cellebrite announced worldwide general availability of Guardian Investigate, an AI-powered investigative management solution designed to let investigators ask questions of evidence, build timelines across files and manage cases collaboratively while maintaining chain of custody (Key Developments).
Cellebrite introduced early access to Cellebrite Genesis, an agentic AI product aimed at helping investigators analyze a wide range of digital evidence through a conversation-like interface. The company also reported earnings guidance for first quarter 2026 revenue of US$126 million to US$128 million and full year 2026 revenue of US$565 million to US$571 million (Key Developments).

Valuation Changes

Fair Value: $21.67 is unchanged, indicating the updated inputs did not move the modelled fair value per share.
Discount Rate: decreased slightly from 10.58% to 10.48%, reflecting a small adjustment in the required return used in the valuation work.
Revenue Growth: essentially flat at 17.51%, with the updated figure rounding to the same level as before.
Net Profit Margin: effectively unchanged at 17.19%, suggesting no material revision to long run profitability assumptions.
Future P/E: decreased slightly from 63.83x to 63.66x, pointing to a marginally lower multiple applied to future earnings in the model.

0 views

Key Takeaways

Accelerating digital crime and security demands are boosting adoption of Cellebrite's forensic SaaS platforms, driving strong subscription growth and deeper customer relationships.
Emphasis on privacy compliance, AI innovation, and recurring revenue is expanding market opportunities, supporting premium pricing, and improving margins and valuation prospects.
Heavy reliance on US federal contracts, regulatory headwinds, and competition-driven R&D needs threaten Cellebrite's growth, margins, and diversification, increasing risks of revenue volatility and market erosion.

Catalysts

About Cellebrite DI

Develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

The accelerating shift by law enforcement and intelligence agencies toward more advanced digital investigation platforms, driven by surging digitalization, larger data volumes, and increasing crime sophistication, is fueling rapid adoption of Cellebrite's cloud/SaaS solutions and digital forensics platforms (Inseyets, Guardian, Pathfinder), which is set to drive continued double-digit subscription revenue and ARR growth over the coming years.
Heightened global security focus, including rising budgets for defense and intelligence (especially in Europe amid geopolitical tension and in the US as new federal allocations are released), is expected to result in a sharp resurgence of demand and larger contract values in 2026, supporting a return to higher top-line growth and increased customer stickiness.
Strengthening privacy and data protection regulations are paradoxically expanding the need for Cellebrite's forensically-sound, compliant data access and investigation tools, reinforcing the company's competitive positioning, supporting premium pricing, and helping sustain high gross margins.
Ongoing innovation in AI-powered analytics and automation, as well as the integration of strategic acquisitions like Corellium (expanding access to ARM device forensics and new private sector verticals), is set to increase Cellebrite's total addressable market (TAM), improve product differentiation, and support both revenue and margin expansion over the long term.
The continued transition to a recurring, subscription-based revenue model-with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration-improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.

Cellebrite DI Earnings and Revenue Growth

Cellebrite DI Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cellebrite DI's revenue will grow by 17.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 16.4% today to 17.2% in 3 years time.
Analysts expect earnings to reach $132.7 million (and earnings per share of $0.48) by about April 2029, up from $77.8 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 63.9x on those 2029 earnings, up from 45.2x today. This future PE is greater than the current PE for the US Software industry at 30.1x.
Analysts expect the number of shares outstanding to grow by 5.14% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.48%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Cellebrite's over-reliance on U.S. federal government contracts introduces significant revenue instability; ongoing delays and constrained visibility into federal spending cycles, combined with procurement and budget bottlenecks, led management to lower guidance and signal that near-term ARR growth is materially impacted-with the company explicitly noting that the federal segment's slow recovery subtracts approximately 4 percentage points from total ARR growth for 2025, directly limiting revenue and earnings growth.
Heightened competition and rapid advances in mobile OS security (notably Apple and Google anti-forensics measures) continue to necessitate escalating R&D investment to sustain Cellebrite's lawful access capabilities; if device manufacturers and privacy advocates successfully harden devices or limit data accessibility faster than Cellebrite can innovate, the long-term relevance and pricing power of Cellebrite's solutions may erode, compressing margins and jeopardizing market share.
Increasing global privacy regulations and tightening data protection laws (such as GDPR, CCPA, and new standards emerging in Europe and other regions) could place greater restrictions on digital evidence extraction, potentially shrinking Cellebrite's addressable market, adding compliance costs, and placing downward pressure on future revenue growth-especially as public and political resistance to digital surveillance grows.
Although international and private sector expansion are highlighted as growth drivers (with recent momentum in EMEA, Latin America, and early Corellium sales), the company's commentary indicates these segments remain a small portion of overall revenue-leaving Cellebrite exposed to geographic and customer concentration risk that could limit earnings diversification and increase volatility during sector-specific demand shocks.
Ambitious investments in AI-driven innovation and acquisitions (such as Corellium) carry execution and integration risks; failure to deliver anticipated operational efficiencies, premium product capabilities, or market expansion could result in elevated costs without corresponding revenue or gross margin improvement, constraining net income and potentially disappointing investors counting on high-margin, innovation-led growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $21.67 for Cellebrite DI based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $18.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $771.9 million, earnings will come to $132.7 million, and it would be trading on a PE ratio of 63.9x, assuming you use a discount rate of 10.5%.
Given the current share price of $14.1, the analyst price target of $21.67 is 34.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cellebrite DI?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cloud SaaS Solutions Will Drive Digital Forensics Adoption